Canada markets close in 5 hours 27 minutes

Sosei Group Corporation (SOLTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
8.440.00 (0.00%)
As of 11:05AM EDT. Market open.

Sosei Group Corporation

PMO Hanzomon
11th Floor 2-1 Kojimachi Chiyoda-ku
Tokyo 102-0083
81 3 5210 3290

Full Time Employees197

Key Executives

NameTitlePayExercisedYear Born
Mr. Shinichi TamuraFounder & Chairman1.1MN/A1949
Mr. Chris CargillRepresentative Exec. Officer, Pres, CEO & Director760.45kN/A1984
Mr. Hironoshin NomuraSr. VP of Investor Relations, VP & Corp. Strategy, Exec. Officer and CFON/AN/AN/A
Mr. Kieran Johnson F.C.A.Exec. Officer, VP & Chief Accounting OfficerN/AN/AN/A
Dr. Miles CongreveChief Scientific OfficerN/AN/AN/A
Mr. Kazuhiko YoshizumiExec. Officer, VP & Chief Compliance OfficerN/AN/A1954
Candelle ChongVP of Corp. Strategy & CommunicationsN/AN/AN/A
Shinichiro NishishitaVP of Investor Relations & Head of Regulatory DisclosuresN/AN/AN/A
Dr. Barry Kenny Ph.D.Chief Bus. Officer of Bus. Devel.N/AN/AN/A
Stacey SouthallAssociate Director & Head of BiophysicsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

Corporate Governance

Sosei Group Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.